Navigation Links
endpoint Adopts New Technology To Boast Most Robust IVR Validation Objective Evidence and Decrease IVR Build Timelines
Date:6/22/2012

ge for IVR systems; however, RealityCorp’s ClinTest Voice offers endpoint a rapidly configurable way to create test scripts in an exceptionally user friendly product. The expectation that endpoint set for success criteria during their trial phase was simple; be able to save several days in testing to provide our Clients even faster turn around times and create a more consistent, bug free product to our End Users. endpoint was able to achieve this with the added benefit of the ClinTest Voice’s objective evidence documentation.

RealityCorp’s ClinTest Voice has made automated testing possible within the Clinical Trial space by:

  •     Allowing test engineers to create easy to use, configurable test scripts for even the most dynamic randomization or drug dispensation scenarios.
  •     Offering the testing team the option to never have to dial into the IVR again.
  •     Producing accurate, relevant testing objective evidence that is comprehendible at any level.
  •     Provide the most robust objective evidence by fully integrating with the associated IVR Database, providing maximum visibility for all validation activities – including data setup

About endpoint
endpoint is an innovative company dedicated to the development of the leading Integrated Voice Response (IVR/IWR) technology platforms for the life sciences industry. endpoint’s founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations.

Read the full story at http://www.prweb.com/releases/2012/6/prweb9630085.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
2. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
3. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
4. Positive Clinical Study Results for BSPs HyperQ Technology
5. Arizona State University engineers aim to improve performance of technology in extreme environments
6. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
7. Pitt discoveries in quantum physics could change face of technology
8. Verenium to Present at Baird Clean Technology Conference
9. Puma Biotechnology Announces Completion of Private Placement
10. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
11. Animal Biotechnology - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
(Date:9/19/2014)... rather than electricity, to move data would consume ... a growing concern as chips, transistor counts rise. ... circuits light emitters, modulators, and detectors ... light source for optical chips is molybdenum disulfide ... as a single, atom-thick layer. Other experimental on-chip ...
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
(Date:9/19/2014)... , September 19, 2014 , ... European Society for Paediatric Endocrinology (ESPE) Meeting  ... and medical research in the field of growth  , ... Darmstadt, Germany , today announced the ... for 2014. The awards were announced during a Satellite ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... by Rice University has brought a wealth of new information ... The current issue of the American Chemical Society journal ... the Rice lab of chemist Bruce Weisman to understand how ... in this case, the light they emit at near-infrared ...
... Realty Trust, Inc. (NYSE: BMR ) today announced ... ended December 31, 2011 after the market closes on Wednesday, ... and Chief Executive Officer, Kent Griffin, President, Matt McDevitt, Executive ... host an investor conference call at 10:00 a.m. Pacific Time ...
... DURHAM, N.C., Jan. 31, 2012  Argos Therapeutics Inc., ... immune monitoring analysis of AGS-003-006, a Phase 2 ... with sunitinib in patients with advanced renal cell ... correlation between anti-tumor memory T cell responses and ...
Cached Biology Technology:Perfect nanotubes shine brightest 2BioMed Realty Trust to Report 2011 Fourth Quarter and Year End Results 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3
(Date:9/18/2014)... tropical rabbitfish which have devastated algal forests in the ... entire Mediterranean basin if their distribution continues to expand ... study, by an international team of researchers led by ... Tomas of the Mediterranean Institute for Advanced Studies in ... ., Members of the team surveyed more than 1000 ...
(Date:9/18/2014)... form of camouflage: you don,t just blend in, the ... as uncommon as you might think. Kathryn Feller, from ... the larval life stages of many marine species are ... that most creatures cannot make transparent. Feller explains that ... individual eye unit with an opaque pigment to prevent ...
(Date:9/17/2014)... Humanities has received a $260,000 grant from the Andrew ... of the Human in the Age of the Life ... of events aimed at exploring two compelling themes in ... who are exploring the boundaries of our self-definition as ... other involves the increasingly influential hypothesis that we are ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... are two root causes of a type of diabetes associated ... a clinical trial, may guide development of new treatments or ... Almost half of patients with CF will develop diabetes by ... their teens. In addition to the health problems caused by ...
... CORVALLIS, Ore. Diatoms, tiny marine life forms that ... biofuel production from algae truly cost-effective because they ... biomedical products and even health foods. Engineers at ... the envelope a bit. But it,s not science fiction ...
... and pregnant, your baby isn,t destined to a life of ... online in The FASEB Journal . In ... fat intake during pregnancy to a moderate level is enough ... they found that a protein called "SIRT1" rewrites a developing ...
Cached Biology News:Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 2Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 3Ancient diatoms could make biofuels, electronics and health food -- at the same time 2Eating well during pregnancy reduces baby's obesity risk regardless of mom's size 2
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
... Antigen peptide transporter 2 ... (Peptide transporter PSF2) (Peptide ... (Peptide transporter involved in ... Antigen: ...
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Biology Products: